Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
A series of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives were designed, synthesized, and evaluated for their topoisomerase I and II inhibition and cytotoxic activity against several human cancer cell lines. Compounds 10-19 showed moderate topoisomerase I and II inhibitory activity and 20-29 showed significant topoisomerase II inhibitory activity. Structure-activity relationship study revealed that 4-(5-chlorofuran-2-yl)-2-(thiophen-3-yl) moiety has an important role in displaying topoisomerase II inhibition.
Thapa
Pritam
P
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Karki
Radha
R
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Choi
Hoyoung
H
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Choi
Jae Hun
JH
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Yun
Minho
M
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Jeong
Byeong-Seon
BS
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
Jung
Mi-Ja
MJ
College of Pharmacy, Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Republic of Korea.
Nam
Jung Min
JM
College of Pharmacy, Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Republic of Korea.
Na
Younghwa
Y
College of Pharmacy, Catholic University of Daegu, Kyongsan 712-702, Republic of Korea.
Cho
Won-Jea
WJ
College of Pharmacy, Chonnam National University, Kwangju 500-757, Republic of Korea.
Kwon
Youngjoo
Y
College of Pharmacy, Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Republic of Korea.
Lee
Eung-Seok
ES
College of Pharmacy, Yeungnam University, Kyongsan 712-749, Republic of Korea.
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004264:DNA Topoisomerases, Type I / Q000737:chemistry / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000737:chemistry / Q000378:metabolism; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D015394:Molecular Structure; D011725:Pyridines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011725:Pyridines; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II; C023666:pyridine